Varma Mutual Pension Insurance Co Purchases Shares of 15,000 IQVIA Holdings Inc. $IQV

Varma Mutual Pension Insurance Co purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 15,000 shares of the medical research company’s stock, valued at approximately $2,898,000.

Other large investors have also made changes to their positions in the company. Financial Freedom LLC acquired a new stake in IQVIA in the 1st quarter valued at approximately $25,000. Ascentis Independent Advisors acquired a new stake in shares of IQVIA in the first quarter worth $25,000. International Assets Investment Management LLC bought a new position in IQVIA during the fourth quarter worth $27,000. Gilpin Wealth Management LLC acquired a new position in IQVIA during the 4th quarter valued at $27,000. Finally, CrossGen Wealth LLC bought a new stake in IQVIA in the 4th quarter valued at $28,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of research analyst reports. Morgan Stanley reaffirmed an “equal weight” rating and set a $200.00 price objective (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. BMO Capital Markets lifted their target price on IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. William Blair upgraded IQVIA to a “strong-buy” rating in a research note on Tuesday, July 28th. HSBC reiterated a “buy” rating and issued a $240.00 price objective on shares of IQVIA in a research report on Monday, July 6th. Finally, Weiss Ratings raised IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and an average price target of $241.88.

IQVIA Price Performance

Shares of IQV stock opened at $260.17 on Monday. The stock’s fifty day simple moving average is $213.32 and its 200 day simple moving average is $187.21. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $260.40. The firm has a market cap of $42.82 billion, a price-to-earnings ratio of 32.28, a P/E/G ratio of 2.21 and a beta of 1.18.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.03 by $0.12. The company had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, analysts expect that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its board has approved a share repurchase program on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its stock is undervalued.

Insider Activity

In other news, insider Eric Sherbet sold 5,000 shares of IQVIA stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the sale, the insider directly owned 20,999 shares in the company, valued at $5,232,110.84. This trade represents a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Bhavik Patel sold 1,855 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the sale, the insider owned 1,348 shares in the company, valued at approximately $317,143.96. This represents a 57.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 12,913 shares of company stock worth $3,098,793 in the last 90 days. Corporate insiders own 1.70% of the company’s stock.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.